CoChat

Induction of Adipocyte Complement-Related Protein of 30 Kilodaltons by PPAR Agonists: A Potential Mechanism of Insulin Sensitization

Terry P. Combs · 2002 · Endocrinology
Cited by 125

The DOI matches its OpenAlex record.

Abstract

Adipocyte complement-related protein of 30 kDa (Acrp30, adiponectin, or AdipoQ) is a fat-derived secreted protein that circulates in plasma. Adipose tissue expression of Acrp30 is lower in insulin-resistant states and it is implicated in the regulation of in vivo insulin sensitivity. Here we have characterized the ability of PPARγ agonists to modulate Acrp30 expression. After chronic treatment of obese-diabetic (db/db) mice with PPARγ agonists (11 d), mean plasma Acrp30 protein levels increased (>3×). Similar effects were noted in a nongenetic type 2 diabetes model (fat-fed and low-dose streptozotocin-treated mice). In contrast, treatment of mice (db/db or fat-fed) with metformin or a PPARα agonist did not affect plasma Acrp30 protein levels. In a cohort of normal human subjects, 14-d treatment with rosiglitazone also produced a 130% increase in circulating Acrp30 levels vs. placebo. In addition, circulating Acrp30 levels were suppressed 5-fold in patients with severe insulin resistance in association with dominant-negative PPARγ mutations. Thus, induction of adipose tissue Acrp30 expression and consequent increases in circulating Acrp30 levels represents a novel potential mechanism for PPARγ-mediated enhancement of whole-body insulin sensitivity. Furthermore, Acrp30 is likely to be a biomarker of in vivo PPARγ activation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

OpenAlex · 10.1210/en.143.3.998

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 36

  1. Bowen, 1991, The effect of CP 68,722, a thiazolidinedione derivative, on insulin sensitivity in lean and obese Zucker rats., Metabolism, 40, 1025, 10.1016/0026-0495(91)90124-F · DOI
  2. Berger, 1996, Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-γ: binding and activation correlate with antidiabetic actions in db/db mice., Endocrinology, 137, 4189, 10.1210/endo.137.10.8828476 · DOI · Paper page
  3. Fujiwara, 1988, Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats., Diabetes, 37, 1549, 10.2337/diab.37.11.1549 · DOI · Paper page
  4. Young, 1995, Repeat treatment of obese mice with BRL 49653, a new and potent insulin sensitizer, enhances insulin action in white adipocytes., Diabetes, 44, 1087, 10.2337/diab.44.9.1087 · DOI · Paper page
  5. Wasada, 1996, Effect of pioglitazone (AD-4833) on insulin stimulated glucose disposal in NIDDM, an assessment by the euglycemic hyperinsulinemic clamp method, Diabetes, 45, 73A
  6. Chaiken, 1995, Metabolic effects of darglitazone, an insulin sensitizer, in NIDDM subjects., Diabetalogia, 38, 1307, 10.1007/BF00401763 · DOI
  7. Nolan, 1994, Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone., N Engl J Med, 331, 1188, 10.1056/NEJM199411033311803 · DOI · Paper page
  8. Lehmann, 1995, An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ., J Biol Chem, 270, 12953, 10.1074/jbc.270.22.12953 · DOI · Paper page
  9. Willson, 1996, The structure-activity relationship between peroxisome proliferator-activated receptor γ agonism and the antihyperglycemic activity of thiazolidinediones., J Med Chem, 39, 665, 10.1021/jm950395a · DOI · Paper page
  10. Berger, 1999, Novel peroxisome proliferator-activated receptor (PPAR) γ and PPARδ ligands produce distinct biological effects., J Biol Chem, 274, 6718, 10.1074/jbc.274.10.6718 · DOI · Paper page
  11. Buckle, 1996, Non thiazolidinedione antihyperglycaemic agents. 1:a-heteroatom substituted b-phenylpropanoic acids., Bioorg Med Chem Lett, 6, 2121, 10.1016/0960-894X(96)00383-6 · DOI
  12. Barroso, 1999, Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus, and hypertension., Nature, 402, 880, 10.1038/47254 · DOI · Paper page
  13. Oakes, 1994, A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat., Diabetes, 43, 1203, 10.2337/diab.43.10.1203 · DOI · Paper page
  14. Zierath, 1998, Role of skeletal muscle in thiazolidinedione insulin sensitizer action., Endocrinology, 139, 5034, 10.1210/endo.139.12.6364 · DOI · Paper page
  15. Berger, 1996, An antidiabetic thiazolidinedione potentiates insulin stimulation of glycogen synthase in rat adipose tissue., Endocrinology, 137, 1984, 10.1210/endo.137.5.8612539 · DOI
  16. Vidal-Puig, 1996, Regulation of PPARγ gene expression by nutrition and obesity., J Clin Invest, 97, 2553, 10.1172/JCI118703 · DOI · Paper page
  17. Martin, 2000, Induction of the fatty acid transport protein 1 and acyl-CoA synthase genes by dimer-selective rexinoids suggests that the peroxisome proliferator-activated receptor-retinoid X receptor heterodimer is their molecular target., J Biol Chem, 275, 12612, 10.1074/jbc.275.17.12612 · DOI · Paper page
  18. Berg, 2001, The adipocyte-secreted protein Acrp30 enhances hepatic insulin action., Nature Med, 7, 947, 10.1038/90992 · DOI · Paper page
  19. Scherer, 1995, A novel serum protein similar to C1q, produced exclusively in adipocytes., J Biol Chem, 270, 26746, 10.1074/jbc.270.45.26746 · DOI · Paper page
  20. Fruebis, 2001, Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice., Proc Natl Acad Sci, 98, 2005, 10.1073/pnas.98.4.2005 · doi:10.1073/pnas.98.4.2005 · Paper page
  21. Yamauchi, 2001, The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity., Nat Med, 7, 941, 10.1038/90984 · DOI · Paper page
  22. Kohanski, 1986, Insulin-dependent phosphorylation of the insulin receptor-protein kinase and activation of glucose transport in 3T3–L1 adipocytes., J Biol Chem, 261, 12272, 10.1016/S0021-9258(18)67235-7 · DOI · Paper page
  23. Luo, 1998, Nongenetic mouse models of non-insulin-dependent diabetes mellitus., Metabolism, 47, 663, 10.1016/S0026-0495(98)90027-0 · DOI · Paper page
  24. Von Langen D , ActonJ, AsterS, BergmanJ, DadizA, GrahamD, GrataleD, HanW, JonesB, LiangC, PatelG, SahooS, TolmanR, BergerJ, DoebbesT, LiebowitzM, MacNaulK, MollerD, ZhouG, Indole acetic acids as novel PPARγ agonists. Proc Keystone Symposium: the PPARs. Keystone, CO, 1999, p 33 (Abstract D122)
  25. Weyer, 2001, Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia., J Clin Endocrinol Metab, 86, 1930, 10.1210/jcem.86.5.7463 · DOI · Paper page
  26. Hotta, 2001, Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys., Diabetes, 50, 1126, 10.2337/diabetes.50.5.1126 · DOI · Paper page
  27. Hu, 1996, AdipoQ is a novel adipose-specific gene dysregulated in obesity., J Biol Chem, 271, 10697, 10.1074/jbc.271.18.10697 · DOI · Paper page
  28. Shapiro, 1998, The crystal structure of a complement-1q family protein suggests an evolutionary link to tumor necrosis factor., Curr Biol, 8, 335, 10.1016/S0960-9822(98)70133-2 · DOI · Paper page
  29. Comuzzie, 1997, A major quantitative trait locus determining serum leptin levels and fat mass is located on human chromosome 2., Nat Genet, 15, 273, 10.1038/ng0397-273 · DOI · Paper page
  30. Das, 2001, Chromosomal localization, expression pattern and promoter analysis of the mouse gene encoding adipocyte-specific secretory protein Acrp30., Biochem Biophys Res Commun, 280, 1120, 10.1006/bbrc.2001.4217 · DOI
  31. Okuno, 1998, Troglitazone increases the number of small adipocytes without the changes of white adipose tissue mass in obese Zucker rats., J Clin Invest, 101, 1354, 10.1172/JCI1235 · DOI · Paper page
  32. Bogan, 1999, Two compartments for insulin-stimulated exocytosis in 3T3–L1 adipocytes defined by endogenous ACRP30 and GLUT4., J Cell Biol, 146, 609, 10.1083/jcb.146.3.609 · DOI · Paper page
  33. Zhang, 1994, Potentiation of insulin stimulation of phosphatidylinositol 3-kinase by thiazolidinedione-derived antidiabetic agents in Chinese hamster ovary cells expressing human insulin receptor and L6 myotubes., J Biol Chem, 269, 25735, 10.1016/S0021-9258(18)47309-7 · DOI
  34. Arita, 1999, Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity., Biochem Biophys Res Commun, 257, 79, 10.1006/bbrc.1999.0255 · DOI · Paper page
  35. Maeda, 2001, PPARγ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein., Diabetes, 50, 2094, 10.2337/diabetes.50.9.2094 · DOI · Paper page
  36. Willson, 2000, The PPARs: from orphan receptors to drug discovery., J Med Chem, 43, 527, 10.1021/jm990554g · DOI · Paper page

Cited by

See all 125

Metadata

Authors
Combs, T. P.
Venue
Endocrinology
Published
2002-03-01
Volume
143
Issue
3
Pages
998-1007
ISSN
  • 0013-7227 (ISSN-L)
  • 1945-7170
OpenAlex
W4243857162
Cited by
125
References
0
FWCI
9.51
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Induction of Adipocyte Complement-Related Protein of 30 Kilodaltons by PPAR Agonists: A Potential Mechanism of Insulin Sensitization. https://app.cochat.ai/papers/10.1210/en.143.3.998
The paper
Combs, T. P. (2002). Induction of Adipocyte Complement-Related Protein of 30 Kilodaltons by PPAR Agonists: A Potential Mechanism of Insulin Sensitization. Endocrinology. https://doi.org/10.1210/en.143.3.998

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.